Milestone Biodefense Publication by Elsevier Journal Vaccine
Supplement launched at Sealy Center for Vaccine Development Symposium
Amsterdam, 19 November 2009 – Last week during the ‘Vaccines for Biothreats and Emerging and Neglected Diseases Symposium’ in Galveston TX, USA, the Elsevier journal Vaccine released a supplement dedicated to vaccines for biodefense. This publication provides a comprehensive, state-of-the-art overview on vaccines that have been developed against a diverse group of human and veterinary pathogens, including Bacillus anthracis, smallpox, and blue tongue.
Biodefense has traditionally been associated with defense against biological warfare agents with an emphasis on military applications. However, the events of October 2001 involving envelopes containing anthrax spores sent through the US Postal Service radically changed our thinking about biodefense. We now recognize the need for biodefense to protect both civilian and military populations against biothreat agents. As research continues to develop biodefense countermeasures, it is clear that vaccines are a critical component of the portfolio to control biothreats.
In their editorial in the supplement, the US Guest Editors Alan Barrett (University of Texas Medial Branch), Shan Lu (University of Massachusetts), and Greg Poland (Mayo Clinic Vaccine Research Group) state that, “the progress in development of vaccines for biothreat agents has been remarkable due to the combined efforts of academia, biotechnology companies, larger pharma, governments, and regulatory authorities, and it is our hope that this supplement may serve as a milestone for this process and a useful reference for people interested in knowing the current status of biodefense vaccine development”.
The supplement was launched at the 3rd in a series of symposia around the theme of, ‘The Changing Landscape of Vaccine Development’, organized by the Sealy Center for Vaccine Development at the University of Texas Medical Branch in Galveston TX, USA in conjunction with the James W. McLaughlin Fellowship Fund.
The symposium Co-Chair and Co-Guest Editor of the Vaccine Supplement, Alan Barrett judged the conference a great success and said: “By focusing on the progression of biodefense vaccine development from bench to bedside the symposium very successfully brought together experts from industry, academia and government to discuss the latest developments in discovery, preclinical development, clinical trials and vaccine acceptance”.
# # #
Notes to Editors:
To receive a copy of Vaccine Volume27, Supplement 4, 5 November 2009; Vaccines for Biodefense (Guest editors Alan D.T. Barrett, Shan Lu, and Gregory A. Poland), please contact the Executive Publisher of Vaccine at firstname.lastname@example.org.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Floris de Hon
+31 20 485 2498